title: Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
abstract: Dendritic cells from patients with cancer are deficient in number and functional activity, leading to inadequate tumor immunosurveillance as a result of poor induction of T-cell antitumor responses. Loaded dendritic cell therapy is a vaccination strategy aimed at eliciting tumor antigen-specific, T-cell immune responses. Loaded dendritic cell therapy using prostatic acid phosphatase (APC8015; Provenge, Dendreon Corp., Seattle, WA) as an immunogen has shown a survival benefit in patients with metastatic hormone-refractory prostate cancer in a randomized phase III trial. This review will summarize the prostate cancer clinical trials using APC8015 and discuss the potential future role of APC8015 in prostate cancer treatment.
authors.affiliation: Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA.
authors.forename: Amy M
authors.initials: AM
authors.lastname: Lin
authors.forename: Robert M
authors.initials: RM
authors.lastname: Hershberg
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Small
mesh_terms: D000135:Acid Phosphatase; D000938:Antigen-Presenting Cells / Q000201:enzymology* / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D017027:Protein Tyrosine Phosphatases / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases